Yuhan Corporation Signs 84.3 Billion KRW API Export Deal for AIDS Treatment
Yuhan Corporation announced on the 20th that it has signed a supply agreement with Gilead Sciences for active pharmaceutical ingredients (API) used in AIDS treatments.
The contract is valued at approximately 84.3 billion KRW, which is equivalent to 4.08% of the company's sales. The contract period runs from March next year to February 2027.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "I Will Give Them a Chance for Self-Examination": Chinese Scientific Community Shaken by Influencer's Preemptive Whistleblowing
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Previously, in September last year, Yuhan Corporation signed a supply agreement with Gilead worth 107.6 billion KRW for APIs used in human immunodeficiency virus (HIV) treatments, and in May this year, it entered into an additional supply agreement valued at 88.8 billion KRW.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
